Evotec banks $10M from its risk-sharing research projects

German contract developer Evotec pocketed €8 million ($10 million) from its ongoing R&D collaborations with Bayer and Johnson & Johnson ($JNJ), capping a big year for the innovative company.

With Bayer, Evotec is working on a 5-year collaboration signed in 2012 in which the pair are trying to identify new treatments for endometriosis. Evotec advanced some molecules from the discovery stage into preclinical development, triggering a payout as it works toward delivering three clinical candidates for the disease.

With J&J's Janssen unit, Evotec is working on NMDA-antagonist portfolio for development against CNS diseases, saying it reached an "important validation milestone" on a new compound, which led to an undisclosed payout.

The revenue will count toward Evotec's 2014 haul, the company said, contributing to its expected single-digit growth on the year.

The company is looking forward to a big 2015 as it prepares to sign an expansive deal with Sanofi ($SNY) in which the drugmaker will invest at least €250 million ($310 million) over 5 years in Evotec, handing over a French research site and forging deep R&D ties with the company.

Evotec splits its business into two halves: EVT Execute, which operates like a CRO, and EVT Innovate, which outlicenses internally developed candidates. The former half largely pays the bills, thanks to risk-sharing deals with the likes of Boehringer Ingelheim and Roche ($RHHBY), but Evotec has taken strides to build up its internal efforts through acquisitions and licensing agreements.

- read the statement

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.